Michael Dickinson, MBBS, D Med Sc, FRACP, FRCPA

Michael Dickinson is the Lead of the Aggressive Lymphoma disease group within Clinical Hematology at Peter MacCallum Cancer Centre and Royal Melbourne Hospital. He specializes as a principal investigator in phase I/II clinical trials of new anticancer drugs with a current focus on Aggressive Lymphomas and novel immunotherapies, and with experience across a breadth of hematological malignancies. His investigator-initiated studies have focused on the role of epigenetic modifiers in hematological malignancies, eltrombopag as a supportive care agent in MDS/AML, and new CART therapies. Dr. Dickinson’s clinical research includes industry and investigator-led trials in aggressive lymphoma, phase 1 studies, and CART trials. Dr. Dickinson is a leading investigator in pivotal clinical trials of CART for Follicular Lymphoma (ELARA, tisagenlecleucel) and DLBCL (Zuma7, Zuma12 and BELINDA). He is an investigator on phase 1 studies of CART and CAR-NK cell trials and is the senior author in the CD20/CD3 bispecific glofitamab phase 1 and pivotal trial and combination program. He has over 100 publications including in New England Journal of Medicine, Nature Medicine, the Journal of Clinical Oncology and Blood.

Dr. Dickinson’s greatest professional satisfaction comes from making individual patients feel better. He believes in research-led clinical care, and placing a patient’s individual circumstances to the fore when developing a treatment plan that is not only evidence-based, but which is also right for them.